Biotech company Vitroscope has secured $7 million in new funding. The capital consists of a $5 million seed round led by Cerberus Ventures and YZR Capital, alongside $2 million in non-dilutive funding from the Research Council of Norway. Other participants in the round included Arcas Ventures, Golden Egg Check, Devico Invest, and several angel investors. This latest injection brings the company's total funding to $8.8 million.
The startup develops automated perfusion platforms designed to study immune activity and disease mechanisms in living human tissue. Its flagship product, vitro.alive, allows researchers to control oxygen levels, pH, temperature, and flow for six parallel experiments. The platform is compatible with standard inverted microscopes and existing tissue models, enabling longitudinal data collection that static well plates cannot provide.
Vitroscope plans to use the capital to support the commercial rollout of vitro.alive and to validate its upcoming high-throughput platform, vitro.scale. The new system is designed to support 96 parallel experiments. Customer testing for vitro.scale is scheduled to commence in 2027, with a full market launch targeted for 2028. The company currently holds multiple international patents for its technology.
The platform has demonstrated its capabilities in several research applications. In one study, Vitroscope and Instant Bio maintained vascularized human brain organoids for seven days. Other tests showed primary human liver cells forming organized tissue on the platform, and kidney cells lacking the AdipoR1 receptor exhibiting impaired responses to fluid flow. These results highlight the platform's role in generating data for drug discovery.
